Q-omics provides the consensus-scored PMS2CL profile across patient tissues and cancer cell-line models. PMS2CL expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in KICH. Among the 18 cancer types available for tumor–normal comparison, PMS2CL is differentially expressed in 15, with the highest sampling consensus in HNSC. Additionally, PMS2CL RNA expression shows 19,985 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight KICH, HNSC, and ACC as cancer lineages where PMS2CL shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PMS2CL — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PMS2CL survival associations across molecular data types. PMS2CL RNA expression shows survival associations in the most cancer types (20), followed by mutation status (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PMS2CL RNA expression–survival associations across cancer types. High PMS2CL expression shows unfavorable associations in KICH, CESC, COAD, UVM, ACC and LIHC. The KICH Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KICH as the clearest survival context for PMS2CL RNA expression.
This table summarizes PMS2CL tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for PMS2CL. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PMS2CL shows higher tumor expression in HNSC, KIRC, BLCA, LUAD, COAD and KIRP. The HNSC box plot shows higher PMS2CL RNA expression in tumor versus normal tissue (log2 FC = +0.710, t-test p < 0.001).
This table shows molecular features associated with PMS2CL in patient tissues and cancer cell lines. In patient samples, PMS2CL shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, PMS2CL RNA and mutation anchors are most strongly linked to RNA-expression features, especially in UPPER_AERODIGESTIVE_TRACT.
